(Q51564935)

English

Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome.

scientific article published in March 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

1 reference

based on heuristic

inferred from title

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

author name string

Morris RS

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Karande VC

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Dudkiewicz A

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Morris JL

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Gleicher N

5

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

language of work or name

0 references

publication date

1 March 1999

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Fertility and Sterility

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

71

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

452-456

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

The Impact of Insulin Secretion on the Ovarian Response to Exogenous Gonadotropins in Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Potential indications for octreotide in endocrinology

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Can metformin reduce insulin resistance in polycystic ovary syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

From somatostatin to Sandostatin: history and chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Endocrine applications of the somatostatin analogue octreotide (Sandostatin)

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

Ovarian hyperstimulation syndrome: an update review.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900475-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0015-0282(98)00475-0

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10065781

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51564935&oldid=1588289122"